August 1, 2021

AstraZeneca Admits Setback to Antibody Treatment

Since the start of the vaccination, AstraZeneca has been “under fire” for various situations. After the blood clots, recently an employee of the European Medicines Agency (EMA, in the English acronym) even indicated the prohibition of the vaccine (something that was denied by the EMA itself).

Now AstraZeneca has admitted a setback in antibody treatment.


AstraZeneca Treatment has the designation AZD7442

Antibody treatment, with the designation AZD7442, was in phase three of development, that is, in large-scale clinical trials to assess its safety and efficacy. However, AstraZeneca today admitted a setback in the development of this solution as its effectiveness has not been proven in clinical trials in people who have been exposed to the virus.

The trial did not achieve the main objective of preventing symptomatic cases of COVID-19 after exposure

According to the agency France-Presse, these clinical trials involved 1,121 adult volunteers who were not vaccinated and who had been exposed to an infected person during the previous eight days, and the treatment reduced the risk of developing covid-19 with symptoms by 33 % of this universe.

COVID-19: AstraZeneca Admits Setback in Antibody Treatment

According to the pharmaceutical company and according to Lusa, trials will continue to assess the effectiveness of the antibodies in people before being exposed to the virus and in patients who have developed severe forms of COVID-19.

The development of this treatment is funded by the US administration, which signed an agreement with AstraZeneca to receive up to 700,000 doses this year.

Still according to the information, in total, the value of the agreements for the development of the treatment for the delivery of the doses reaches 726 million dollars (about 600 million euros) this year, with AstraZeneca advising today that they are negotiations “on next steps with the United States Government” take place.